Endurance RP Ltd
HKEX:575

Watchlist Manager
Endurance RP Ltd Logo
Endurance RP Ltd
HKEX:575
Watchlist
Price: 1 HKD Market Closed
Market Cap: HK$291.8m

Relative Value

The Relative Value of one Endurance RP Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 1 HKD, Endurance RP Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Endurance RP Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Endurance RP Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Endurance RP Ltd
HKEX:575
291.8m HKD 40.8 -9.2 -9.9 -9.8
US
Eli Lilly and Co
NYSE:LLY
1.1T USD 17.7 57 38.2 41
US
Johnson & Johnson
NYSE:JNJ
564.7B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
282.5B CHF 4.6 30.2 12.7 14.9
US
Merck & Co Inc
NYSE:MRK
294.9B USD 4.5 16.2 10.1 11.8
CH
Novartis AG
SIX:NOVN
226B CHF 5.2 20.2 12.7 16.4
UK
AstraZeneca PLC
LSE:AZN
212.5B GBP 5.1 31.5 15.1 22
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.9 9 10.5
US
Pfizer Inc
NYSE:PFE
153.2B USD 2.4 19.7 7.4 9.8
FR
Sanofi SA
PAR:SAN
98.3B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
HK
Endurance RP Ltd
HKEX:575
Average P/E: 24.1
Negative Multiple: -9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
57
54%
1.1
US
Johnson & Johnson
NYSE:JNJ
21.1
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.2
29%
1
US
Merck & Co Inc
NYSE:MRK
16.2
14%
1.2
CH
Novartis AG
SIX:NOVN
20.2
17%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.5
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
2%
6.5
US
Pfizer Inc
NYSE:PFE
19.7
26%
0.8
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
Endurance RP Ltd
HKEX:575
Average EV/EBITDA: 46.1
Negative Multiple: -9.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.1
7%
1.4
CH
Novartis AG
SIX:NOVN
12.7
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
1%
9
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
Endurance RP Ltd
HKEX:575
Average EV/EBIT: 98.7
Negative Multiple: -9.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
18
6%
3
CH
Roche Holding AG
SIX:ROG
14.9
6%
2.5
US
Merck & Co Inc
NYSE:MRK
11.8
6%
2
CH
Novartis AG
SIX:NOVN
16.4
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
9.8
-1%
N/A
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3